Patents
Literature
4760 results about "Antibody" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein produced mainly by plasma cells that is used by the immune system to neutralize pathogens such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the pathogen, called an antigen, via the fragment antigen-binding (Fab) variable region. Each tip of the "Y" of an antibody contains a paratope (analogous to a lock) that is specific for one particular epitope (similarly, analogous to a key) on an antigen, allowing these two structures to bind together with precision. Using this binding mechanism, an antibody can tag a microbe or an infected cell for attack by other parts of the immune system, or can neutralize its target directly (for example, by inhibiting a part of a microbe that is essential for its invasion and survival). Depending on the antigen, the binding may impede the biological process causing the disease or may activate macrophages to destroy the foreign substance. The ability of an antibody to communicate with the other components of the immune system is mediated via its Fc region (located at the base of the "Y"), which contains a conserved glycosylation site involved in these interactions. The production of antibodies is the main function of the humoral immune system.
Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
PendingUS20250249116A1Special deliveryAntibody mimetics/scaffoldsMyotonic dystrophy geneMyotonic dystrophy
Aspects of the disclosure relate to compositions comprising a plurality of complexes comprising an antibody (e.g., anti-TfRI antibody) covalently linked to one or more oligonucleotides (e.g. a DMPK targeting oligonucleotide), each oligonucleotide being covalently linked at a linkage site represented by a lysine (K) residue of the antibody. In some embodiments, the antibody comprises a heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region, and a light chain comprising a light chain variable region (VL) and a light chain constant region, wherein at least 80% (e.g., 80%-98%, 80%-95%, 80%-90%, 85%-98%, 85%-95%, 85%-90%, 90%-98%, 90%-95%, 95%-97%, or more) of the light chain constant regions of the antibodies of the complexes in the composition are independently covalently linked to an oligonucleotide at a linkage site represented by K188 (based on Kabat numbering) and / or a linkage site represented by K190 (based on Kabat numbering) of the light chain constant regions of the antibodies.
Owner:DYNE THERAPEUTICS INC
Dosing of muscle targeting complexes for treating myotonic dystrophy
Aspects of the disclosure relate to methods of reducing expression or activity of DMPK (e.g., reducing the level of a mutant or wild-type DMPK RNA, or the activity of a DMPK gene product) and / or methods of treating myotonic dystrophy (e.g., DM1) in a subject. In some embodiments, the methods comprise administering to the subject a composition comprising complexes (e.g., muscle targeting complexes) comprising an oligonucleotide (e.g., a DMPK—targeting oligonucleotide) covalently linked to an antibody (e.g., anti-TfR1 antibody).
Owner:DYNE THERAPEUTICS INC
Recombinant herpes zoster vaccine as well as preparation method and application thereof
ActiveCN119386170Ahigh titerstrong immune responseAntibody mimetics/scaffoldsViral antigen ingredientsHerpes zoster virusHerpes Zoster Vaccine
The invention discloses a recombinant herpes zoster vaccine as well as a preparation method and application thereof, and particularly relates to the technical field of biological medicines. The recombinant herpes zoster vaccine comprises a recombinant herpes zoster vaccine fusion protein purified product HN101 and a liposome mixture HA201, and the recombinant herpes zoster fusion protein gE-gD is constructed by recombining reconstructed gE protein and reconstructed gD protein. The gE-gD recombinant herpes zoster fusion protein is obtained by reconstructing gE protein of varicella-herpes zoster virus and gD protein of HSV through a gene recombination technology and then recombining the gE protein and the gD protein. After the gE-gD recombinant herpes zoster fusion protein is combined with a liposome mixture HA201, stronger immune response can be induced, the antibody titer and cellular immunity are improved, the vaccine effect is enhanced, and meanwhile, the potential infection risk is avoided.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD
Computer network security situation awareness system and method
The invention discloses a computer network security situation awareness system and method, and relates to the technical field of computer network security, and the method comprises the steps: generating a dynamic gene pool through an antigen-antibody matching algorithm based on an initial quantum trust vector, and building a mapping relation table of an antigen feature vector and an antibody defense strategy; triggering a quantum alarm according to an entanglement entropy mutation event in the real-time quantum state flow data, matching a biological antibody strategy corresponding to a current network attack feature based on a mapping relation table, and fusing the quantum alarm and the biological alarm to generate an attack path topological graph; the network security situation is perceived by analyzing the quantum state change of the abnormal node ID and combining an attack path topological graph and a dynamic gene pool. Quantum entanglement pairs are distributed to network nodes through the quantum key distribution center, and initial quantum trust vectors are generated, so that the unknown attack resisting capability of the network is remarkably improved, and efficient and accurate network security situation awareness is realized.
Owner:BEIJING MUXUE COMPUTER TECHNOLOGY CO LTD
Immune microbubble complex and its uses
The present invention relates to an immunomicrobubble complex and its uses. The immunomicrobubble complex (IMC) according to the present invention comprises microbubbles conjugated with an antibody, wherein the microbubbles have excellent stability and excellent antibody binding strength, and it has been confirmed that when the immunomicrobubble complex is treated with high-intensity focused ultrasound (HIFU), the anti-tumor effect is significantly enhanced and an immune-enhancing effect is exhibited. Therefore, the immunomicrobubble complex according to the present invention is expected to improve the delivery efficiency of the conjugated antibody and can be used for the diagnosis and treatment of cancer, and exhibits various functions in the field of immunotherapy, including a contrast effect, improvement of half-life, improvement of drug delivery, lymphocyte concentrating effect, cancer immunotherapy, and ultrasound-induced immunotherapy.
Owner:IMGT
Homodimeric antibodies for use in treating cancers and methods of use
ActiveUS20250127942A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsSperm proteinCancer research
This disclosure relates to homodimeric antibodies for use in treating cancer generally and to both homodimeric antibodies that bind human sperm protein 17 (Sp17) and homodimeric antibody immunoconjugates specifically. Such homodimeric antibodies display improved properties relative to monomeric antibodies, for example, because they can crosslink cells, improve cellular uptake, and / or carry greater payloads.
Owner:MEDICOVESTOR INC
Single cell proteomics using degradable hydrogels
The present disclosure is directed to methods for measuring proteomes of single cells. In one aspect, methods comprise disposing cells on a surface, synthesizing hydrogel chambers around each of the cells, lysing the cells to release intracellular proteins for adsorption onto the surface bounded by the hydrogel chambers, depolymerizing the hydrogel chambers, and quantifying the adsorbed proteins with detection antibodies to determine the single cell proteomes.
Owner:CELLANOME INC
Antibodies that bind interleukin 13 and methods of use
Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and / or IgE.
Owner:APOGEE THERAPEUTICS INC
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Methods and kits using nucleic acid encoding and / or label
Methods and Kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and / or nucleic acid recording of a molecular interaction and / or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Assays that do not require the cyclic transfer of information between a coding tag and a recording tag are also disclosed, including single cycle assays.
Owner:2026 DF PEPTIDE ACQUISITION LLC
Inflammation factor detection kit based on liquid-based chip technology
InactiveCN119470918AReduce the difficulty of detectionHigh detection throughputDisease diagnosisBiological testingInflammatory factorsChemical reaction
The invention relates to the technical field of biological detection, and provides an inflammatory factor detection kit based on a liquid-based chip technology, and the inflammatory factor detection kit comprises six fluorescent microspheres coupled with capture antibodies, and six detection antibodies labeled by report fluorescence; in the six fluorescent microspheres containing the captured antibodies, the fluorescence intensities of all the fluorescent microspheres are different; according to the detection kit provided by the invention, on the basis of a liquid-based chip technology, fluorescein is adopted to carry out fluorescence coding on microspheres, and a captured antibody is connected to the fluorescent microspheres through a chemical reaction; a detection target is captured through the fluorescent microspheres, and then a signal is displayed through the detection antibody, so that the detection of the inflammatory factors is completed, the defects of large demand quantity of soluble inflammatory factor detection samples, long detection time, tedious detection steps and the like in the prior art are overcome, and great convenience is brought to scientific researchers at a hospital end and an industrial end.
Owner:SUZHOU ZHIYAN MEDICAL TECHNOLOGY CO LTD
Droplet preparation instrument and antibody screening device
The utility model discloses a liquid drop preparation instrument and an antibody screening device, and the liquid drop preparation instrument comprises a chip assembly which comprises a liquid drop generation chip and a liquid drop sorting chip, and the liquid drop sorting chip comprises a sorting electrode; the sample table is used for placing at least one of the liquid drop generating chip and the liquid drop sorting chip; the optical module is optically coupled with the sample table and is used for providing incident light to the sample table and collecting an optical signal generated by the biological sample or the liquid drop in response to the incident light; the liquid path system is in operable conduction with the chip assembly and is used for pumping a solution to the liquid drop generating chip or the liquid drop sorting chip; the control circuit can selectively call a first group of control parameters or a second group of control parameters, the first group of control parameters comprises a first control instruction, and the second group of control parameters comprises a second control instruction; the control circuit comprises a feedback control sub-circuit used for controlling the sorting electrodes. According to the liquid drop preparation instrument, liquid drop preparation can be carried out, and needed liquid drops can be rapidly sorted out.
Owner:MGI TECH CO LTD
Composition and method for the diagnosis and treatment of iron-related disorders
PendingUS20250179159A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsBiochemistryAntibody
Owner:ABBVIE DEUTSCHLAND GMBH & CO KG +1
Dosing regimen for treating inflammatory bowel disease
ActiveUS12304956B1Digestive systemPharmaceutical delivery mechanismDosing regimenInflammatory bowel disease
Owner:PARAGON THERAPEUTICS INC
SIRP antibodies for treatment of hemophagocytic lymphohistiocytosis
PCT designated stage expiredWO2025085854A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsHemophagocytic lymphohistiocytosisAntibody
Owner:ELECTRA THERAPEUTICS INC
Nanometer antibody specifically binding to AAV9 and application thereof
The invention belongs to the technical field of nano antibodies, and particularly relates to a nano antibody specifically bound with AAV9 and application of the nano antibody. The nano antibody provided by the invention can be specifically combined with the AAV9 adeno-associated virus without being combined with other AAV serotypes such as AAV2, AAV5 and AAV8, so that high-sensitivity and high-specificity detection of the AAV9 adeno-associated virus is realized. In practical application, the nano-antibody coupled solid-phase carrier provided by the invention is adopted as an affinity filler, the AAV9 adeno-associated virus can be effectively captured and mildly eluted, the virus purification and recovery effects are effectively improved, and the nano-antibody coupled solid-phase carrier is suitable for high-purity recovery of the AAV9 adeno-associated virus.
Owner:SHANGCHUN BIOTECHNOLOGY (WUHAN) CO LTD
Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
PendingUS20260001964A1Organic active ingredientsHybrid immunoglobulinsAntigen Binding FragmentCell Surface Antigens
The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and / or tumor-associated antigen; and (c) a binding site for human FcγRI, FcγRIIa and / or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and / or FcγRIII than to human FcγRIIb.
Owner:LINDIS BIOTECH GMBH
Short peptide composition for inhibiting inclusion body formation and promoting self-assembly of Gag-Like protein nanoparticles
The invention discloses an oligopeptide composition for inhibiting inclusion body formation and promoting Gag-Like protein nanoparticle self-assembly, the oligopeptide composition comprises a C-terminal oligopeptide and an N-terminal oligopeptide, the amino acid sequence of the N-terminal oligopeptide is as shown in SEQ ID NO: 1, and the amino acid sequence of the C-terminal oligopeptide is as shown in SEQ ID NO: 2. The oligopeptide composition can effectively avoid formation of a prokaryotic expression protein inclusion body and / or promote dissolution of prokaryotic expression protein, the oligopeptide composition is further utilized to be combined with HIV-1p24 and human endogenous retrovirus K capsid protein CA, nanoparticles are prepared respectively, and the oligopeptide composition can be used as a carrier for antigen surface display or drug transportation. The nanoparticles formed by the HIV-1 capsid protein p24 and the human HERV K CA have cavities which are obviously larger than those of ferritin, so that the nanoparticles have higher loading capacity; as an antigen display platform, the antibody also has good stability and wide applicability.
Owner:SUN YAT SEN UNIV
RNA for in VIVO transfection with increased expression
PCT designated stage expiredWO2025096878A1Polypeptide with localisation/targeting motifPowder deliveryOpen reading frameDelivery vehicle
This disclosure provides improved RNA molecules, including mRNA molecules that can be produced by in vitro transcription and are suitable for in vivo transfection using an appropriate delivery vehicle, such as a lipid nanoparticle (LNP) or targeted lipid nanoparticle (tLNP). The improved RNA include particular combinations of 5' untranslated region (UTR) and 3' UTR, particular 3' UTRs, or particular open reading frame sequences. Also provided herein are compositions of the LNP, or tLNP with an antibody as a targeting moiety, such as anti-CD8 antibodies that are used as targeting moiety.
Owner:CAPSTAN THERAPEUTICS INC
Separation method of bovine ephemeral fever virus, obtained bovine ephemeral fever virus and application of bovine ephemeral fever virus
ActiveCN120249227ASsRNA viruses negative-senseViral antigen ingredientsCytopathic effectBovine ephemeral fever
The invention discloses a separation method of a bovine ephemeral fever virus, the obtained bovine ephemeral fever virus and application of the bovine ephemeral fever virus. Belongs to the technical field of bovine ephemeral fever virus separation. The invention aims to provide an efficient and rapid method for separating the bovine ephemeral fever virus. The invention provides a method for separating bovine ephemeral fever virus, which comprises the following steps: inoculating a bovine anticoagulant sample to KC cells for culture, harvesting virus, inoculating to grow into monolayer BHK-21 cells, and carrying out passage to obtain passage cells with cytopathy of the first generation; the virus strain can also be used for screening, preparing and detecting a bovine ephemeral fever virus antibody and preparing a bovine ephemeral fever virus infected animal model.
Owner:HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)
Sample pretreatment automation method for flow detection
The invention provides a sample pretreatment automation method for flow cytometry, and belongs to the technical field of sample pretreatment for flow cytometry. A biological sample to be detected is collected and placed in a collection tube containing an EDTA-K2 anticoagulant for pretreatment; an automatic pipetting system is used for carrying out incubation reaction on an anticoagulant whole blood sample and an intelligent matching fluorescence labeling antibody mixed solution, and a double-layer game optimization verification system is used for verifying the rationality of an antibody adding proportion and reaction condition parameters; carrying out fluorescence characteristic readability index prediction on the incubated cell suspension by adopting an intelligent dilution parameter regulator model, dynamically adjusting hemolysis parameters and suspension conditions, and adding 1 * hemolysin working solution by using an automatic liquid adding device to carry out hemolysis treatment so as to finish pretreatment; the technical problems that in the pretreatment process of flow cytometry detection samples, parameters are often based on artificial experience, and the reproducibility and standardization degree of detection results are insufficient are solved.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD
Five-item combined detection test strip for inflammation of peripheral blood
The invention discloses a test strip for five-item combined detection of inflammation of peripheral blood as well as a preparation method and application of the test strip. The test strip comprises a PVC bottom plate, a nitrocellulose membrane, a glass cellulose membrane combination pad, a sample pad and a water absorption pad, the PVC bottom plate is located at the bottommost part, and the sample pad, the glass cellulose membrane combination pad, the nitrocellulose membrane and the water absorption pad are sequentially arranged above the PVC bottom plate; the nitrocellulose membrane is provided with an HBP, PCT, IL-6, CRP and SAA detection line and a mouse anti-DNP monoclonal antibody quality control line; the glass nitrocellulose membrane combination pad is provided with a combination of a fluorescent microsphere-labeled HBP antibody, a fluorescent microsphere-labeled PCT antibody, a fluorescent microsphere-labeled IL-6 antibody, a fluorescent microsphere-labeled CRP antibody, a fluorescent microsphere-labeled SAA antibody and a fluorescent microsphere-labeled DNP-BSA. According to the test strip, fluorescence immunochromatography is carried out by utilizing the principle of a double-antibody sandwich method in combination with the characteristics of fluorescent microspheres, and rapid, specific, simple, convenient and sensitive joint detection on HBP, PCT, IL-6, CRP and SAA is realized at the same time.
Owner:SHANXI KANGJIANEN BIOTECHNOLOGY CO LTD
Software development automation test case generation system based on artificial intelligence
The invention belongs to the technical field of software development and testing, and discloses an artificial intelligence-based software development automatic test case generation system, which is characterized in that an immune heuristic case self-repairing module is adopted, defects are regarded as antigens, antibody cases capable of being self-updated are generated by using a clone selection algorithm, and a gene rearrangement mechanism is automatically triggered when an interface is changed, so that the test efficiency is improved. The details of the use case are adjusted while the core detection logic is reserved; compared with a traditional method, the mechanism can realize use case dynamic adaptation without manual intervention, the maintenance workload is remarkably reduced, and the method is particularly suitable for a complex software system with frequent iteration; the space-time coupling test scene generation engine fuses dynamic scenes such as interaction and state transition of a module and short-time operation after precise coverage login by using a space-time convolutional network; the cross-dimension holographic use case synthesis module integrates multi-source data such as codes, hardware and user behaviors through tensor decomposition to generate a composite use case; functions and performance of software in a complex scene can be comprehensively verified, and test blind areas are remarkably reduced.
Owner:SHANDONG BIAOFAN INFORMATION TECH CO LTD
Monoclonal antibody BY017 combined with African swine fever virus P30 protein and application thereof
ActiveCN120484103AImmunoglobulins against virusesAntibody ingredientsClassical swine fever virus CSFVWestern blot
The invention discloses a monoclonal antibody BY017 combined with African swine fever virus P30 protein and application of the monoclonal antibody BY017. The invention provides an IgG antibody which is composed of a light chain and a heavy chain. CDR1, CDR2 and CDR3 in the heavy chain variable region are sequentially shown as the 47 to 54 , the 72 to 79 and the 118 to 126 in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region are sequentially as shown in the 49 to 60 , the 78 to 80 and the 117 to 124 in SEQ ID NO: 3. The invention also protects the application of any one of the IgG antibodies in preparation of products. The product has the functions that the product is used for being combined with an African swine fever virus P30 protein fragment; the antibody is used for binding African swine fever virus P30 protein; the antibody is used for binding African swine fever virus. The IgG antibody provided by the invention can be used for multiple purposes of western blot, immunohistochemistry, flow cytometry, ELISA (Enzyme-Linked Immunosorbent Assay) and the like, and can be used as an important tool for ASFV detection and structural analysis of P30 protein of ASFV detection.
Owner:베이징 중커 란위 바이오테크놀로지 씨오 엘티디 +1
Sortilin-based lysosome targeting chimera and application thereof
PendingCN120554529AAntibody mimetics/scaffoldsAntibody ingredientsLysosomal targetingExtracellular proteins
The invention discloses a lysosome targeted chimera based on Sortilin and application thereof. The lysosome targeted chimera comprises a ligand molecule of a lysosome targeted receptor and a ligand molecule of a targeted protein to be degraded, wherein the ligand molecule and the ligand molecule are connected through a linker; the lysosome targeting receptor is Sortilin, and the ligand molecule of the lysosome targeting receptor is a polypeptide targeting the Sortilin; the protein to be degraded is membrane protein or extracellular protein. Furthermore, the polypeptide of the targeted Sortilin is connected with an enzyme response sequence and an integrin receptor targeting sequence. According to the invention, the Sortilin-combined ligand neurotensin is functionally coupled with the neutralizing antibody or polypeptide of overexpression protein in targeted tumor or inflammatory diseases, and the Sortilin-combined ligand neurotensin has obvious treatment gain in malignant solid tumor and psoriasis models. The discovery promotes the transformation potential of the lysosome participating in the biological agent, and provides a dual strategy for realizing accurate degradation through receptor recruitment and microenvironment induction.
Owner:ZHEJIANG UNIV
Il-18 fusion proteins and methods of producing il-18
PendingCN120051292APolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsReticulum cellWhite blood cell
Fusion proteins are provided that consist of essential elements such as one or more proteins / polypeptides capable of transporting into the endoplasmic reticulum (ER) and fragments or variants of interleukin 18 (IL-18) or IL-18. The proteins / polypeptides capable of transporting into the ER include, but are not limited to, immune globular proteins (e.g., Fc regions, VHH antibodies, and scFv), and globular proteins (e.g., serum albumin). In some embodiments, the IL-18 may be a pro-IL-18 similar to a natural precursor cytokine, wherein IL-18 is fused to the C-terminus of a propeptide or a propeptide variant thereof. In some embodiments, the fusion protein may further comprise a cleavable peptide linker.
Owner:FUSE BIOTHERAPEUTICS INC
Interleukin 21 variants
The disclosure provides interleukin 21 (IL-21) variants that have (i) decreased or no binding to a human interleukin 21 receptor (IL-21R) as compared to a wild-type human IL-21 polypeptide; or (ii) increased stability as compared to a wild-type human IL-21 polypeptide; or (iii) decreased or no binding to a human interleukin 21 receptor (IL-21R) as compared to a wild-type human IL-21 polypeptide and increased stability as compared to a wild-type human IL-21 polypeptide. The disclosure also provides fusion proteins including an antibody or fragment thereof bound, e.g., covalently linked, to an IL-21 variant.
Owner:A-ALPHA BIO
New class of molecules for selective clearance of antibody
The present invention relates to a new class of molecules for selective clearance of antibodies and the uses thereof for treating antibody-mediated diseases and disorders.
Owner:OSE IMMUNOTHERAPEUTICS SA
Adjuvant and application thereof in vaccine preparation
ActiveCN119504957Agood immune protectionSsRNA viruses negative-senseSsRNA viruses positive-senseTGE VACCINEType Vaccine
The invention discloses an adjuvant and application thereof in vaccine preparation. The amino acid sequence of the adjuvant is shown as SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 23, 27, 31, 35 or 39. The immune protection effect of the nanoparticle vaccine can be improved by activating TLR2, and good vaccine adjuvant activity is shown in a common immunogen SD or new coronavirus RBD immunogen model. Furthermore, an assembly construction method of the self-adjuvant-nanoparticle vaccine is optimized, and the prepared self-adjuvant-nanoparticle vaccine has a remarkable effect of inducing the generation of an antibody in an animal body. The novel adjuvant provided by the invention can be widely applied to vaccine research and development, and meanwhile, the assembled nanoparticle self-adjuvant vaccine can also become a novel vaccine.
Owner:SUN YAT SEN UNIV